Biomarkers for diagnosis of infection in cancer patients with febrile neutropenia

What is it about?

Novel tools are needed for diagnosis of infection in cancer patients with febrile neutropenia. We have evaluated the utility of pancreatic stone protein and soluble CD25. Our results suggest that these emergent biomarkers don not enhace the diagnostic accuracy of procalcitonin, which is the biomarker commonly used in clinical practice

Featured Image

Why is it important?

The availabity of tools to identify the infectious or non infectious origin of febrile neutropenia is a key for risk stratification and making decission in cancer patients with FN admitted to an ED. We have evaluated the diagnostic accuracy of two emergent biomarkers, PSP and sCD25, in comparison with a conventional biomarker, such as PCT